The Advances in Pharmacology series presents a variety of chapters from the best authors in the field.
1. Cover image - p. page_i 2. Title page - p. page_i 3. Table of Contents - p. page_i 4. Copyright - p. page_iv 5. Contributors - p. page_xi 6. Preface: Remembering Ronald Stanton Duman, Ph.D - p. page_xv 7. Part I: Neurobiology of ketamine effects - p. page_xvi 8. Chapter One: Effects of ketamine and other rapidly acting antidepressants on hippocampal excitatory and inhibitory transmission - p. page_xvi 9. Chapter Two: Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition - p. page_41 10. Chapter Three: The role of eEF2 kinase in the rapid antidepressant actions of ketamine - p. page_78 11. Part II: The rapid therapeutic effects of ketamine - p. page_99 12. Chapter Four: Clinical overview of NMDA-R antagonists and clinical practice - p. page_99 13. Chapter Five: Ketamine for depression clinical issues - p. page_129 14. Chapter Six: Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence - p. page_162 15. Chapter Seven: Neurobiological biomarkers of response to ketamine - p. page_194 16. Chapter Eight: Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants - p. page_235 17. Chapter Nine: The emergence of ketamine as a novel treatment for posttraumatic stress disorder - p. page_259 18. Part III: Novel rapid-acting antidepressant mechanisms related to ketamine - p. page_285 19. Chapter Ten: mGlu2/3 receptor as a novel target for rapid acting antidepressants - p. page_285 20. Chapter Eleven: Involvement of muscarinic receptor mechanisms in antidepressant drug action - p. page_309 21. Chapter Twelve: The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions - p. page_356
The Advances in Pharmacology series presents a variety of chapters from the best authors in the field.
1. Cover image - p. page_i 2. Title page - p. page_i 3. Table of Contents - p. page_i 4. Copyright - p. page_iv 5. Contributors - p. page_xi 6. Preface: Remembering Ronald Stanton Duman, Ph.D - p. page_xv 7. Part I: Neurobiology of ketamine effects - p. page_xvi 8. Chapter One: Effects of ketamine and other rapidly acting antidepressants on hippocampal excitatory and inhibitory transmission - p. page_xvi 9. Chapter Two: Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition - p. page_41 10. Chapter Three: The role of eEF2 kinase in the rapid antidepressant actions of ketamine - p. page_78 11. Part II: The rapid therapeutic effects of ketamine - p. page_99 12. Chapter Four: Clinical overview of NMDA-R antagonists and clinical practice - p. page_99 13. Chapter Five: Ketamine for depression clinical issues - p. page_129 14. Chapter Six: Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence - p. page_162 15. Chapter Seven: Neurobiological biomarkers of response to ketamine - p. page_194 16. Chapter Eight: Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants - p. page_235 17. Chapter Nine: The emergence of ketamine as a novel treatment for posttraumatic stress disorder - p. page_259 18. Part III: Novel rapid-acting antidepressant mechanisms related to ketamine - p. page_285 19. Chapter Ten: mGlu2/3 receptor as a novel target for rapid acting antidepressants - p. page_285 20. Chapter Eleven: Involvement of muscarinic receptor mechanisms in antidepressant drug action - p. page_309 21. Chapter Twelve: The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions - p. page_356
